Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Transparent GelMA biomaterials: Advanced solutions for ocular tissue engineering and regenerative ophthalmology

Chai M., He Q., Yao B., Wei R.

Narrative Review on Face & Skin, published in Adv Ophthalmol Pract Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Ophthalmol Pract Res (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41909588
PMCID
PMC13019815
DOI
10.1016/j.aopr.2026.01.001
Citations
1

Abstract (original English)

Background The complex and sensitive nature of ocular tissues demands innovative biomaterials for effective repair and regeneration. Gelatin methacryloyl (GelMA) hydrogel has emerged as a highly promising candidate due to its excellent biocompatibility, tunable mechanical properties, and adaptability to advanced fabrication techniques like 3D bioprinting. Main text This review provides a comprehensive analysis of GelMA's applications across key areas of ocular surface therapy. It first covers its role in sutureless repair of corneal and conjunctival injuries, where photocurable adhesives offer rapid wound closure. A major focus is on artificial cornea development, detailing strategies for enhancing mechanical strength, incorporating bioactive components and utilizing 3D/4D printing to mimic native corneal architecture. Furthermore, GelMA serves as an effective platform to treat limbal stem cell deficiency (LSCD) and as a drug-eluting system for managing keratitis and dry eye, featuring stimuli-responsive release mechanisms. However, challenges remain, including immune response concerns, long-term biosafety of photoinitiators, and the lack of standardized manufacturing protocols. Conclusions GelMA represents a versatile foundation for next-generation ophthalmic biomaterials. Future progress hinges on establishing long-term safety profiles, developing intelligent composites with

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research